Label Adherence for Non-Vitamin K Antagonist Oral Anticoagulants in a Prospective Cohort of Asian Patients with Atrial Fibrillation by �뾼�옱�꽑 & �젙蹂댁쁺
277www.eymj.org
Label Adherence for Non-Vitamin K Antagonist 
Oral Anticoagulants in a Prospective Cohort 
of Asian Patients with Atrial Fibrillation
So-Ryoung Lee1*, Young Soo Lee2*, Ji-Suck Park1, Myung-Jin Cha1, Tae-Hoon Kim3, Junbeom Park4, 
Jin-Kyu Park5, Jung-Myung Lee6, Ki-Woon Kang7, Jaemin Shim8, Jae-Sun Uhm3, Jun Kim9, Changsoo Kim10, 
Jin-Bae Kim6, Hyung Wook Park11, Boyoung Joung3, and Eue-Keun Choi1
1Department of Internal Medicine, Seoul National University Hospital, Seoul; 
2Division of Cardiology, Catholic University of Daegu, Daegu; 
3Division of Cardiology, Yonsei University College of Medicine, Seoul; 
4Department of Cardiology, College of Medicine, Ewha Womans University, Seoul; 
5Division of Cardiology, Hanyang University Medical Center, Seoul; 
6Division of Cardiology, Kyung Hee University Medical College, Seoul; 
7Division of Cardiology, Eulji University Hospital, Daejeon; 
8Division of Cardiology, Korea University Anam Hospital, Seoul; 
9Department of Internal Medicine, University of Ulsan College of Medicine, Seoul; 
10Department of Preventive Medicine, Yonsei University College of Medicine, Seoul; 
11Department of Cardiovascular Medicine, Chonnam National University Medical School, Gwangju, Korea.
Purpose: Label adherence for non-vitamin K antagonist oral anticoagulants (NOACs) has not been well evaluated in Asian pa-
tients with non-valvular atrial fibrillation (AF). The present study aimed to assess label adherence for NOACs in a Korean AF pop-
ulation and to determine risk factors of off-label prescriptions of NOACs.
Materials and Methods: In this COmparison study of Drugs for symptom control and complication prEvention of AF (CODE-AF) 
registry, patients with AF who were prescribed NOACs between June 2016 and May 2017 were included. Four NOAC doses were 
categorized as on- or off-label use according to Korea Food and Drug Regulations. 
Results: We evaluated 3080 AF patients treated with NOACs (dabigatran 27.2%, rivaroxaban 23.9%, apixaban 36.9%, and edoxa-
ban 12.0%). The mean age was 70.5±9.2 years; 56.0% were men; and the mean CHA2DS2-VASc score was 3.3±1.4. Only one-third 
of the patients (32.7%) was prescribed a standard dose of NOAC. More than one-third of the study population (n=1122, 36.4%) 
was prescribed an off-label reduced dose of NOAC. Compared to those with an on-label standard dosing, patients with an off-la-
bel reduced dose of NOAC were older (≥75 years), women, and had a lower body weight (≤60 kg), renal dysfunction (creatinine 
clearance ≤50 mL/min), previous stroke, previous bleeding, hypertension, concomitant dronedarone use, and anti-platelet use. 
Conclusion: In real-world practice, more than one-third of patients with NOAC prescriptions received an off-label reduced dose, 
which could result in an increased risk of stroke. Considering the high risk of stroke in these patients, on-label use of NOAC is rec-
ommended.
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INTRODUCTION
Adjusted doses of warfarin can be prescribed according to pro-
thrombin time in order to achieve a target therapeutic win-
dow, which necessitates frequent monitoring.1 In comparison, 
non-vitamin K antagonist oral anticoagulants (NOACs) exert a 
predictable effect without requiring standard anticoagulation 
monitoring and are suitable alternatives to warfarin for stroke 
prevention in patients with atrial fibrillation (AF). Their use in 
clinical practice is increasing rapidly.2-4 Although the dosage of 
NOAC is not determined by the results of anticoagulation test 
results, each NOAC has a recommended dose based on clini-
cal characteristics (e.g., age, body weight, renal function, and 
concomitant medications). The efficacy and safety of the rec-
ommended doses of each NOAC to prevent stroke in patients 
with AF have been confirmed in pivotal randomized clinical 
trials.5-9 All of these phase 3 trials, except for the RE-LY trial, 
have provided criteria for dose reduction, which physicians can 
apply to reduce NOAC doses to decrease the risk of bleeding. 
In real-world practice, off-label use of a reduced dose of NOAC 
is not uncommon. In recent reports in the U.S., 13–16% of pa-
tients received off-label NOAC doses, and the majority of these 
patients were prescribed with underdosing.10,11 Although re-
duced doses of NOACs might be considered as an improve-
ment in safety by lowering the risk of bleeding in fragile pa-
tients, off-label underdosing of NOACs has been shown to be 
associated with an increased risk of stroke without a benefit in 
safety.10,11 
Compared to Western populations, Asian patients with AF 
are smaller and have a higher risk of bleeding. Accordingly, 
physicians prefer to prescribe a reduced dose of NOAC more 
frequently than physicians in the Western countries.12-14 How-
ever, there is a paucity of information on whether these re-
duced doses of NOAC meet the criteria for dose reduction. There-
fore, we sought to assess label adherence for NOACs and to 
identify risk factors associated with off-label prescriptions of 
NOACs in real-world practice in a Korean population. 
MATERIALS AND METHODS
Data source 
The COmparison study of Drugs for symptom control and com-
plication prEvention of AF (CODE-AF) registry is a prospec-
tive, multicenter, observational study of AF patients enrolled 
at 10 tertiary centers in Korea. The study design and centers 
have been described previously.15 The first database of the 
CODE-AF registry for analysis was released in May 2017 with 
patients from June 2016 to April 2017. The data entered at 
each center were regularly audited, and the database used in 
this study completed data cleansing. The collected data were 
registered in the web-based clinical research management 
system iCReaT (Internet based Clinical Research and Trial 
management system, http://icreat.nih.go.kr) provided by the 
Korean government. The study protocol conforms to the ethi-
cal guidelines of the 1975 Declaration of Helsinki; the study 
was approved by the ethics committee of each center; and all 
study patients provided informed consent and were registered 
at ClinicalTrials.gov (NCT02786095). The study was approved 
by the Seoul National University Hospital Institutional Review 
Board (IRB Number: 1605-082-76). 
Study population
Among the 6275 patients enrolled in the CODE-AF registry, 
we included patients who were prescribed a NOAC for stroke 
prevention (n=3213). Patients without available dose informa-
tion were excluded. Patients without information for evalua-
tion of compliance with labeled dosing, such as age, sex, body 
weight, or serum creatinine value, were also excluded. We also 
excluded patients with end-stage renal disease who were on 
dialysis. 
Dose reduction criteria 
A standard dose was defined, according to each NOAC, as dab-
igatran 150 mg twice daily, rivaroxaban 20 mg once daily, apix-
aban 5 mg twice daily, and edoxaban 60 mg once daily. Ap-
proved dose reduction criteria were specific to each NOAC 
according to the following patient characteristics: baseline age, 
body weight, and serum creatinine level at enrollment. Creati-
nine clearance (CrCl) was calculated using the Cockcroft-Gault 
equation. 
In the present study, adherence with labeled dosing for each 
NOAC in each study patient was evaluated based on the Min-
istry of Food and Drug Safety labeling (Supplementary Table 1, 
only online). 
Evaluation of NOAC dosing according to label
Patients were categorized into four groups based on NOAC 
dose and dose recommendation adherence: on-label standard 
dose, on-label reduced dose, underdosed, and overdosed. To 
identify predictors of those who had an underdosed prescrip-
tion, we compared the clinical characteristics between patients 
who were prescribed an on-label standard dose and those with 
an underdose who needed to be prescribed the standard dose. 
Exclusively for dabigatran, both the 150 mg and 110 mg twice 
daily doses were regarded as on-label use, because dabigatran 
does not have mandatory dose reduction criteria for selected 
patients.5,9 Therefore, dabigatran 110 mg twice daily prescrip-
tion was defined as the on-label reduced dose, regardless of 
patients’ baseline characteristics. Instead, the Ministry of Food 
and Drug Safety labeling recommended the use of dabigatran 
110 mg bid in those with CrCl 30–50 mL/min or age ≥75 years. 
Therefore, for patients prescribed with a reduced dose of dab-
igatran, we defined the patients who met one of these criteria 
as “recommendation-concordant prescription,” and those 
who did not meet any of these criteria as “recommendation-
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discordant prescription.”16 
Comparison of dose reduction criteria among NOACs 
Differences in dose reduction criteria for each NOAC could 
result in a discrepancy in prescriptions with standard or reduced 
doses among the NOACs. For example, one NOAC should be 
prescribed with a standard dose, whereas another NOAC could 
be prescribed with a reduced dose. To evaluate this discrep-
ancy in dose reductions among NOACs, we applied dose re-
duction criteria to each NOAC of the total population, evalu-
ated the dose reduction criteria of the four NOACs in each 
patient, and determined which NOAC could be prescribed as 
a labeled reduced dose, whereas other NOACs could not.
Statistical analysis
Continuous variables are presented as means and standard de-
viations. Comparison of continuous variables was performed 
using an independent t-test or, in case of a non-normal distri-
bution, the Mann-Whitney test. Categorical variables are pre-
sented as numbers and percentages and were compared us-
ing the chi-square test of Fisher’s exact test. To assess factors 
associated with the prescription of off-label reduced doses of 
NOACs, univariate binary logistic regression analysis was used. 
All variables with p<0.1 in the univariate analysis were used for 
multivariate logistic regression analysis. The CHA2DS2-VASc 
and HAS-BLED scores were excluded in the multivariable lo-
gistic regression because of interactions with variables includ-
ed in the clinical scores. Sensitivity analysis was performed 
including CHA2DS2-VASc and HAS-BLED scores. Odds ratios 
were calculated as an estimate of the risk associated with a par-
ticular variable with a 95% confidence interval based on bino-
mial distributions. All statistical analyses were performed with 
SPSS statistical package version 19.0 (IBM Corp., Armonk, NY, 
USA). All two-tailed p values <0.05 were considered statistically 
significant. 
RESULTS
Baseline characteristics of the study population
We evaluated 3080 AF patients treated with NOACs (dabiga-
tran 27.2%, rivaroxaban 23.9%, apixaban 36.9%, and edoxaban 
12.0%). The baseline characteristics are presented in Supple-
mentary Table 2 (only online). The mean age was 70.5±9.2 
years; 56.0% were men; 34% were under 60 kg; and the mean 
CHA2DS2-VASc score was 3.3±1.4 (CHA2DS2-VASc score ≥2, 
93.1%). Six hundred seventy-seven (22%) patients had moder-
ate renal dysfunction (CrCl <50 mL/min). Eighty-eight (2.9%) 
patients were prescribed dronedarone concomitantly. Among 
the NOAC groups, the apixaban group was older and had a higher 
CHA2DS2-VASc score than the other NOAC groups.
In the total study population, 32.7% of patients were pre-
scribed a standard dose, and 67.3% of patients received a re-
duced dose. There was a difference in the prescription pat-
terns of dose reduction by each NOAC (71.8% in dabigatran, 
69.3% in rivaroxaban, 66.3% in apixaban and 56.6% in edoxa-
ban). Patients taking dabigatran and rivaroxaban were pre-
scribed a reduced dose more frequently than those taking apix-
aban and edoxaban, whereas edoxaban was prescribed as a 
reduced dose in only half of patients (all, p<0.05, Supplementa-
ry Table 2, only online). 
Label adherence for NOAC prescription 
Among the entire study population, on-label users accounted 
for 61.9% (31.1% with a standard dose and 30.8% with a re-
duced dose). Those who were off-label underdosed comprised 
36.4%, and off-label overdosed included 1.6% (Table 1, Fig. 1). 
Most patients taking dabigatran were prescribed labeled used, 
although there were a few patients with off-label use (once daily 
prescription or overdose prescription in 16 cases). Edoxaban 
showed the highest dose recommendation adherence (on-la-
beled use, 68%), whereas rivaroxaban showed the lowest dose 
recommendation adherence (on-labeled use, 43.9%). Among 
those with a standard dose (n=1009), most patients (95%) ad-
hered with the labeling (Fig. 2). Most patients with a standard 
dose of dabigatran, rivaroxaban, and apixaban followed on-la-
bel prescription, while edoxaban showed a higher proportion 
of overdosed prescriptions, compared to other NOACs (0, 7, 0 
and 20%, respectively, p<0.001) (Fig. 2). The reasons for this 
overdose prescription of edoxaban included patients being 
underweight (≤60 kg, n=18), moderate-to-severe renal dys-
function (CrCl 15–50 mL/min, n=6), or both (n=8). Among those 
taking a reduced dose (n=2071), only 46.3% of patients had on-
label use, whereas more than half of patients (53.7%) had off-
label use. 
The proportions of off-label underdosed prescription dif-
fered among NOACs. Rivaroxaban and apixaban showed simi-
lar, but higher, prescriptions of off-label reduced doses (78% 
and 83%, respectively, p=0.051) than edoxaban, whereas the 
edoxaban group showed only 41% of off-label reduced dose 
prescription (rivaroxaban vs. edoxaban, apixaban vs. edoxa-
ban, both p<0.001). The reasons for off-label use in each NOAC 
were as follows: Among 396 patients taking underdosed rivar-
oxaban, 320 (81%) patients had normal renal function, and 76 
(19%) patients were prescribed a dose less than 10 mg. Among 
624 patients with underdosed apixaban, 300 (48%) patients 
met one dose reduction criterion; 274 (44%) patients met no 
dose reduction criteria; and 50 (8%) patients were prescribed a 
once-daily dosage or less than 2.5 mg bid. Among 87 patients 
with underdosed edoxaban, 79 (91%) patients met none of the 
dose reduction criteria, and 8 patients were prescribed a 15 mg 
dosage. Among the patients with a reduced dose of dabigatran, 
40.2% received a recommendation-concordant reduced dose, 
and 59.8% were prescribed a recommendation-discordant re-
duced dose. The reasons for recommendation-discordant use 
in dabigatran included normal renal function (above CrCl 50 
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mL/min, n=480) and age younger than 75 years (n=380). We 
summarized label adherence for each NOAC in Supplementa-
ry Fig. 1 (only online). Apixaban showed the smallest number 
of patients who met the dose reduction criteria (12.9%), 
whereas edoxaban showed the largest number of patients who 
met the dose reduction criteria (43.4%). Compared to real-
world prescriptions, edoxaban showed a smaller discrepancy 
between dose label and prescription, compared to rivaroxaban 
and apixaban (rivaroxaban vs. edoxaban, apixaban vs. edoxa-
ban, both p<0.001).
Risk factors associated with off-label underdosing of 
NOAC
The baseline characteristics by NOAC dosing are presented in 
Table 1. To identify factors associated with off-label underdosed 
NOACs, we compared the baseline characteristics of patients 
prescribed an off-label underdosed NOAC to patients pre-
scribed an on-label standard dose (Supplementary Table 3, 
only online). Relative to the on-label standard dose group, pa-
tients who received off-label underdosed NOACs were signifi-
cantly older, more likely women, had a lower body weight, had 
renal impairment and were more likely to have hypertension 
(all, p<0.001). Compared to those with on-label standard dose 
NOACs, the off-label underdosed group showed significantly 
higher CHA2DS2-VASc scores (mean 3.48±1.41 vs. 2.80±1.39) 
and HAS-BLED scores (mean 2.06±0.82 vs. 1.68±0.92; all, p< 
0.001). Previous bleeding was more common in the off-label 
underdosed group than the on-label standard dose group 
Table 1. Baseline Characteristics according to Labeled Use
On-label standard dose On-label reduced dose Off-label underdose Off-label overdose
Number (proportion, %) 959 (31.1) 949 (30.8) 1122 (36.4) 50 (1.6)
Dose discrepancy 284 (29.6) 483 (50.9) 706 (62.9) 46 (92.0)
Age (yr) 65.2±8.99 73.62±8.77 72.18±7.82 72.28±8.04
Age <65 401 (41.8) 134 (14.1) 165 (14.7) 6 (12.0)
Age 65–74 423 (44.1) 339 (35.7) 473 (42.2) 23 (46.0)
Age ≥75 135 (14.1) 476 (50.2) 484 (43.1) 21 (42.0)
Female 312 (32.5) 487 (51.3) 521 (46.4) 35 (70.0)
Height (cm) 165.47±8.12 160.43±9.48 161.94±9.11 157.48±7.55
Weight (kg) 70.27±11.00 61.68±11.56 64.99±10.70 58.78±7.74
≤60 kg 160 (16.7) 495 (52.2) 370 (33.0) 35 (70.0)
BMI (kg/m2) 25.61±3.26 23.86±3.30 24.76±3.44 23.74±2.99
Serum creatinine (mg/dL) 0.91±0.20 0.95±0.29 0.93±0.27 0.98±0.31
CrCl (mL/min) 79.74±22.54 60.36±23.43 65.46±20.52 53.84±16.52
15–30 0 (0) 53 (5.6) 11 (1.0) 1 (2.0)
30–50 41 (4.3) 327 (34.5) 214 (19.1) 30 (60.0)
≥50 918 (95.7) 569 (60.0) 897 (79.9) 19 (38.0)
Heart failure 138 (14.4) 133 (14.0) 132 (11.8) 4 (8.0)
Hypertension 696 (72.6) 741 (78.1) 898 (80.0) 38 (76.0)
Diabetes 300 (31.3) 281 (29.6) 376 (33.5) 11 (22.0)
Previous stroke/TIA/TE 239 (24.9) 175 (18.4) 229 (20.4) 13 (26.0)
Vascular disease 67 (7.0) 69 (7.3) 81 (7.2) 0 (0)
Previous bleeding 46 (4.8) 92 (9.7) 165 (14.7) 1 (2.0)
Major bleeding 13 (1.4) 18 (1.9) 30 (2.7) 1 (2.0)
Intracranial bleeding 11 (1.1) 15 (1.6) 20 (1.8) 1 (2.0)
CHA2DS2-VASc score 2.80±1.39 3.53±1.42 3.48±1.41 3.58±1.43
Score ≥2 829 (86.4) 913 (96.2) 1077 (96.0) 49 (98.0)
HAS-BLED score 1.68±0.92 2.07±0.85 2.06±0.82 2.04±0.81
Previous warfarin use 45 (4.7) 75 (7.9) 36 (3.2) 5 (10.0)
Concomitant medication
Dronedarone 12 (1.3) 24 (2.5) 50 (4.5) 2 (4.0)
Aspirin 54 (5.6) 77 (8.1) 49 (4.4) 4 (8.0)
Clopidogrel 18 (1.9) 42 (4.4) 72 (6.4) 2 (4.0)
Cilostazol 3 (0.3) 7 (0.7) 8 (0.7) 0 (0)
1 or more antiplatelet use 70 (7.3) 111 (11.7) 124 (11.1) 4 (8.0)
BMI, body mass index; CrCl, creatinine clearance; TE, thromboembolic events; TIA, transient ischemic attack. 
Variables are presented as number (percentage) or mean±standard deviation.
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(14.7% vs. 4.8%, p<0.001), whereas previous thromboembolic 
events (TE) were more common in the on-label standard dose 
group compared to the off-label underdosed group (24.9% vs. 
20.4%, p=0.014). Rates of one or more concomitant antiplate-
let use were significantly higher in the off-label underdosed 
group than the on-label standard dose group (11.1% vs. 7.3%, 
p=0.003). Dronedarone use was more common in the off-la-
bel underdosed group compared to the on-label standard dose 
group (4.5% vs. 1.3%, p<0.001). In the multivariable logistic re-
gression, old age (≥75 years), women, a lower body weight (≤60 
kg), renal impairment (CrCl ≤50 mL/min), prevalent hyper-
tension, previous stroke/transient ischemic attack (TIA)/TE, 
previous bleeding, dronedarone use, and anti-platelet use 
were associated with off-label underdosing (Fig. 3). These 
findings were similar when the CHA2DS2-VASc and HAS-
BLED scores were included in multivariable analysis (Supple-
mentary Table 4, only online).
Each NOAC has different dose reduction criteria and the 
proportions of off-label underdosed prescription were differ-
ent among NOACs. We evaluated the associated factors with 
off-label underdosed prescription in each NOAC group (Sup-
plementary Tables 5–8, Supplementary Fig. 2, only online). 
Although the factors varied across the types of NOACs due to 
patient numbers of each group, the associated factors with off-
label underdosing were largely consistent with the results from 
total study population (Fig. 3). 
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Fig. 2. Label adherence for NOAC dosing in the study population. NOAC, non-vitamin K antagonist oral anticoagulant.
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DISCUSSION
Main findings
In this study, we analyzed label adherence for dosing across 
four NOACs and factors associated with off-label underdosing 
in patients with AF in routine clinical practice. In this large-scale 
Asian AF cohort who were prescribed NOACs, the main find-
ings were as follows: 1) off-label NOAC prescription was fre-
quently observed, and label adherence for NOAC dosing was 
about 60%; 2) most standard doses of NOAC were prescribed 
as in label, although more than half of the reduced doses of 
NOAC were prescribed off-label; 3) edoxaban showed the 
highest dose recommendation adherence, whereas rivaroxa-
ban showed the lowest dose recommendation adherence; 
and 4) old age (≥75 years), women, lower body weight (≤60 
kg), renal impairment (CrCl ≤50 mL/min), prevalent hyper-
tension, previous stroke/TIA/TE, previous bleeding, droneda-
rone use, and anti-platelet use were associated with off-label 
underdosing prescriptions of NOACs. These findings could 
give important insights into real-world NOAC prescription be-
havior in Asian populations.
Dose reduction criteria for individual NOACs and 
their complexity 
Patients taking NOACs have favorable risk-benefit profiles, 
few drug interactions, and require less intensive monitoring 
than those taking warfarin. Therefore, NOACs are being pre-
scribed more frequently for stroke prevention in nonvalvular 
AF.2-4,17 Each NOAC requires a different dose reduction strate-
gy as described in their phase 3 clinical trials (Supplementary 
Table 1, only online). The proportion of patients who indicat-
ed dose reductions were different among pivotal clinical trials 
(Supplementary Fig. 3, only online).5-8 Dabigatran did not have 
dose reduction criteria in RE-LY, and patients were randomly 
assigned doses of 150 mg or 110 mg twice daily.5 In the ROCK-
ET AF trials, 21% of the rivaroxaban group who had moderate 
renal impairment (CrCl 30–49 mL/min) received rivaroxaban 
15 mg once daily.6 In the ARISTOTLE trials, less than 5% of the 
study population was recommended for dose reduction.7 In 
the high-dose regimen edoxaban group in the ENGAGE AF-
TIMI 48 trial, 25% of the patients indicated a dose reduction.8 
We applied dose reduction criteria for each NOAC to the total 
population to calculate the proportion of patients who were 
indicated for a dose reduction (Supplementary Fig. 4, only 
online). Apixaban permitted the smallest proportion of the 
population (9.6%) to use a reduced dose by their drug label, 
whereas edoxaban permitted the largest proportion of the 
population (44%). The proportion of indicated dose reduc-
tions was quite similar in cases of rivaroxaban, compared to 
clinical trials (22% vs. 21%). For apixaban and edoxaban, 
more patients were indicated to have a reduced dose of NO-
ACs in the real-world population, compared with clinical tri-
als (apixaban, 9.6% vs. 4.7%; and edoxaban 44% vs. 25.4%). 
These findings might be caused by a lower body weight in 
Asian populations. Interestingly, the agreement of dose re-
ductions among all four NOAC drug labels was observed only 
in 5.6% of the total study population. Forty-three percent of 
the total population was recommended a standard dose of 
NOAC. However, in 49.3% of patients, a discrepancy in NOAC 
dosing was observed. Therefore, half of patients might be pre-
scribed either a standard dose or reduced dose with different 
NOACs, not violating the dose reduction label. 
Label adherence of NOAC dosing 
The appropriate use of NOACs is an emerging issue. There are 
several reports regarding the labeled use of NOAC in patients 
with AF. Recently, in the ORBIT-AF II (Outcomes Registry for 
Better Informed Treatment of Atrial Fibrillation II) registry, 
12.8% of the total study population received NOACs inconsis-
tent with the drug label (9.4% with an off-label underdose and 
3.4% with an off-label overdose).10 In a large recent U.S. claims 
database, 83.7% of the total patients were prescribed the rec-
ommended dose of NOACs, while 12.0% and 4.3% of the study 
patients received off-label underdose and overdose NOACs, 
respectively.11 Although reduced dose NOACs are commonly 
used in Asian patients with AF, there are no data about “label 
adhered dosing” in the Asian population. According to Tai-
wanese nationwide data, almost 90% of the total study popu-
lation was prescribed a reduced dose of NOACs (110 mg twice 
daily dabigatran and 10 mg to 15 mg once daily rivaroxaban).12 
Additionally, in the Korean nationwide data, 40–60% of the 
patients were prescribed a reduced dose of NOACs.14 Howev-
er, neither studies reported label adherence for NOAC dosing. 
In our study, 67.3% of patients were prescribed a reduced 
dose of NOACs, regardless of label adherence, and 38% of the 
total population did not meet the recommended drug label-
ing use. Most off-label dosing was considered as off-label un-
derdose NOAC use (96% of off-label dosing population). Name-
ly, patients who were a recommended standard dose of NOACs, 
based on their baseline characteristics, frequently received a 
reduced dose of NOACs. 
Odds ratio (95% CI)
4.153 (2.133–8.087)
3.851 (3.058–4.848)
3.403 (2.359–4.910)
3.181 (2.196–4.609)
1.649 (1.289–2.109)
1.606 (1.141–2.161)
1.501 (1.217–1.852)
1.359 (1.083–1.705)
0.674 (0.511–0.819)
p value
<0.001
<0.001
<0.001
<0.001
<0.001
0.007
<0.001
0.008
<0.001
Dronedarone use
Age ≥75 yrs
Previous bleeding
CrCI ≤50 mL/min
Body weight ≤60 kg
Anti-platelet use
Female
Hypertension
Previous stroke/TIA/TE
0.1                 1                   10
On-label standard dose Off-label underdose
Fig. 3. Factors associated with off-label underdosing. CrCl, creatinine 
clearance; TE, thromboembolic events; TIA, transient ischemic attack; 
CI, confidence interval.
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There are several explanations regarding the reason for the 
preference of reduced doses of NOAC prescriptions in the 
Asian population. First, the Asian population has a lower body 
mass, and some clinicians who targeted a low international 
normalized ratio in older adult patients replaced warfarin with 
a reduced dose of NOAC.12 Furthermore, different approved 
doses were used in some Asian countries based on clinical evi-
dence. In Japan, 15 mg rivaroxaban was recommended as a 
standard dose instead of 20 mg, based on the J-ROCKET-AF 
study.18 Second, the Asian population tends to have a higher 
risk of intracranial hemorrhage (ICH) than the Western popu-
lation, for which clinicians feel it important not to increase the 
risk of bleeding.13 Based on these results, we could assume that 
physicians tend to choose reduced dose NOACs for patients 
regarded as more fragile to bleeding. In addition, when patients 
are in the “borderline gray zone” by label, physicians were more 
likely to select a reduced dose NOAC. Compared to the on-la-
bel standard dose group, patients with an off-label underdose 
of NOACs were more likely to have a dosing discrepancy based 
on the drug-specific label (62.9% vs. 29.6%, respectively; p< 
0.001).
Clinical implications of label adherence for NOAC 
dosing
A few previous reports have outlined the clinical consequenc-
es of label adherence. In the ENGAGE AF-TIMI 48 trial, a low-
dose edoxaban regimen posed a significantly higher ischemic 
stroke risk, whereas patients with the same dose of edoxaban 
who met one of the dose reduction criteria showed a compa-
rable risk of stroke to those taking warfarin.8 Recently, adverse 
clinical consequences for off-label dosing have been reported 
from real-world data. In the ORBIT-AF II registry, compared 
to the recommended dose of NOACs, off-label doses of NO-
ACs showed higher adverse events rates.10 Particularly, an off-
label underdose of NOAC was associated with a worsened ef-
fectiveness with no benefit in safety.10,11 Notably, the estimated 
stroke risk was significantly higher in the off-label underdose 
group, compared to the on-label standard dose group. To im-
prove the clinical outcomes of Asian AF patients, an increase 
in label adherence for NOAC dosing might be needed.
Consideration of optimal NOAC doses for Asian AF 
patients 
There are a few reports suggesting that lower dose NOACs re-
garded as “off-label underdose” by current labels could be 
safe and effective in the Asian population. Although 15 mg ri-
varoxaban was recommended as a standard dose in patients 
without renal impairment in the J-ROCEKT-AF trial, the num-
ber of patients was small to generalize for Asian patients.18 
However, although dabigatran showed different positions in 
terms of label adherence, recently, patients prescribed recom-
mendation-discordant 110 mg dabigatran present comparable 
results in effectiveness and safety, compared to patients with 
150 mg dabigatran, among Korean AF patients.16 Based on the 
Taiwanese nationwide cohort, universally-prescribed reduced 
doses of dabigatran and rivaroxaban, regardless of label adher-
ence, showed better effectiveness and safety, compared to the 
real-world warfarin group.12 Considering that Asians have a 
lower body mass, more prevalent ICH, and generally a lower 
time in the therapeutic range, further investigation is needed 
to assess the optimal doses of NOACs and net clinical effects of 
off-label NOAC prescription in the Asian AF population.12,13,19,20
Study limitations
There are several limitations in the present study. We analyzed 
NOAC dosing patterns based on patients and their baseline 
characteristics. However, body weight, renal function, and 
concomitant drug use could be modified during follow-up 
and might affect the physician’s choice of NOAC dosing. In ad-
dition, in this study, we did not include follow-up data; there-
fore, clinical outcomes according to inappropriate NOAC dos-
ing were not evaluated. Further investigation will be needed to 
determine the clinical implications of NOAC dosing in the 
Korean AF population. Lastly, this study analyzed the multi-
center prospective registry of Korean population. Thus, ethnic 
uniformity should be considered, and the generalization of 
the study results should be proceeded with caution. Moreover, 
among East Asian countries, definitions of “on-label dose” for 
rivaroxaban differ, as do proportions of low dose prescription 
of NOACs. Despite these limitations, this study describes a 
prospectively-collected large number of Korean AF patients. 
Our findings reflect the real-world clinical practice patterns of 
NOAC dosing in contemporary Asian patients with AF. 
In conclusion, in real-world practice, half of Korea patients 
treated with NOACs received off-label reduced dose. Older 
age, female sex, lower body weight, impaired renal function, 
previous stroke or bleeding history, hypertension, and con-
comitant dronedarone or antiplatelet agent use were inde-
pendently associated with off-label underdose prescription. 
Further study is needed to investigate the clinical outcomes of 
off-label prescription of NOACs, especially in Asians. 
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